News

These data highlight the results of an international sample of adult patients with allergies to certain food products and caregivers of children with food allergies.

Dunlop provided his opinions on the committee’s comments regarding functional unblinding and cardiovascular implicative risks when it comes to studying MDMA.

Emergency department admissions were linked to not receiving hepatitis C care among hospitalized patients who inject drugs or are living with hepatitis C.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 updates from the 84th American Diabetes Association (ADA) Scientific Sessions.

In this episode, hosts recaps their picks for top diabetes technology-related updates from ADA 2024, including news from Omnipod, MiniMed 780G, and the Tandem mobi.

This analysis explores the burden level in pediatric and adolescent eczema patients within Japan, highlighting associated burden on caregivers/families and other factors.

Gozal told HCPLive about the issue of the classic approach when diagnosing children with OSA.

This June 2024 month in review highlights hepatic pipeline developments, new MASH therapeutics on the road to FDA approval, and the latest installment of Qazi Corner.

In this episode, Veeral Sheth, MD speaks with Alkeus Pharmaceutical's CMO on the company's lead candidate for Stargardt disease and the TEASE clinical trial program.

HCPLive spoke with Joshua M. Cohen, MD, MPH, to discuss a post-hoc analysis of a phase 3 study that showed buprenorphine may be effective at reducing fentanyl use.

Findings highlight the prognostic value of metabolic syndrome components in predicting both renal and cardiovascular outcomes in patients with IgA nephropathy.

Our Cardiology Month in Review for June 2024 spotlights the pharmacotherapies making waves within the pipeline, the latest news in dyslipidemia, and updates in heart failure.

Our June 2024 month-in-review for hematology focuses on the latest updates to the hematologic pipeline.

In this clinical quiz, you will test your knowledge of psoriasis guidelines, with special focus on important clinical questions related to management of psoriasis and recent evidence-based recommendations.

This Month in Review spotlights interviews conducted at SLEEP 2024 and a recent FDA approval.

Shiffman reviews some of the key findings from AHFIRM, explaining important considerations for interpreting the results and potential reasons for regional differences in the data.

Across the Phase 2 ReCLAIM-2 trial, elamipretide demonstrated photoreceptor protection and the potential for visual function improvement in eyes with dry AMD.

These data suggest differences in Medicaid-accepting pediatric dermatologist access based on such factors as geographic area and density of pediatric dermatologists per county.

Family physician Scuderi shares how he helps patients manage PTSD symptoms ahead of Fourth of July fireworks.

This June 2024 month in review spotlights HCPLive’s coverage of the latest renal news and research in IgA nephropathy, differences in care, and novel associations in nephrology.

Robust clinical data showed ustekinumab-ttwe demonstrated similar safety and efficacy compared with the reference product.

Aflibercept-mrbb showed comparable safety, efficacy, pharmacokinetics, and immunogenicity compared with the reference product.

Neurocrine Biosciences was granted Priority Review designations for two crinecerfont NDAs focused on children, adolescents, and adults with classic CAH.

This summary of major dermatology news covered in June highlights stories such as late-breaking data at RAD 2024, recent interviews, and recent FDA news.

This month in review captures the top FDA updates, including the first FDA Advisory Committee meeting to discuss the NDA for a psychedelic-assisted therapy.

Shiffman describes the current treatment landscape for alcohol-associated hepatitis and what larsucosterol might offer for these patients.

Carol Levy, MD, discusses INHALE-3 trial and how to incorporate individual patient-level factors into the management of patients with type 1 diabetes who could benefit from inhaled insulin.

The case series highlighted here was limited due to smaller numbers of participants, necessitating additional real-world data on bimekizumab for psoriasis.